Despite the anti-angiogenesis effects of EGFR-TKIs, no studies on the effects of the EGFR-TKIs Gefitinib, Afatinib, and AZD9291 on lymphangiogenesis in lung cancer have been reported. Here, EGFR is linked to lung cancer.